Anti-PD-L1 (clone; 10F.9G2) were purchased from BioXcell (BioXcell, MA, USA). The reagents were prepared according to the manufacturer's protocol and refrigerated until used. The delivery of the aPD-L1 was performed using the IP injection method, and the dose was injected at 17:30 every Tuesday. aPD-L1 was treated with 5 mg/kg/mice.
Anti pd l1 clone 10f 9g2
Manufactured by BioXCell
Sourced in United States
The Anti-PD-L1 (clone 10F.9G2) is a laboratory reagent that binds to the PD-L1 protein. PD-L1 is a molecule involved in the regulation of the immune system. This reagent can be used in various research applications to study the interactions between PD-L1 and other cellular components.
Automatically generated - may contain errors
Lab products found in correlation
Anti ctla 4 clone 9h10, by BioXCell (3 mentions)
Anti ly 6c clone monts 1, by BioXCell (2 mentions)
Phosphate buffered saline (pbs), by Thermo Fisher Scientific (2 mentions)
Poly 1 c, by InvivoGen (2 mentions)
Anti cd40 agonist clone fgk4, by BioXCell (2 mentions)
Cpg1826, by InvivoGen (2 mentions)
Anti cd48 clone hm48 1, by BioXCell (2 mentions)
C57bl 6 mice, by Charles River Laboratories (1 mentions)
Ltf 2, by BioXCell (1 mentions)
Rat igg2b, by BioXCell (1 mentions)
Anti pd l1 10f 9g2, by BioXCell (1 mentions)
Anti human cd3, by BioLegend (1 mentions)
Anti ifn γ clone xmg1, by BioXCell (1 mentions)
Lps e coli o55 b5, by Merck Group (1 mentions)
Control rat igg2b clone ltf 2, by BioXCell (1 mentions)
Anti ctla4 clone 9d9, by BioXCell (1 mentions)
Ctla4 ig, by Bristol-Myers Squibb (1 mentions)
Anti cd28 dab, by Bristol-Myers Squibb (1 mentions)
Control vκ dab, by Bristol-Myers Squibb (1 mentions)
Anti cd8α clone 2, by BioXCell (1 mentions)
30 protocols using anti pd l1 clone 10f 9g2
1
Anti-PD-L1 Immunotherapy in Mice
2
Syk Conditional Knockout Mouse Tumor Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The conditional myeloid Syk knock out mouse strain (SykMC-KO) and their wild type control (SykMC-WT) are from the C57BL/6 background and were generated by crossing floxed Syk mice with lysozyme M (LysM) Cre recombinase transgenic mice as described previously (41 (link)). 4-6-week-old C57BL/6 mice used in these experiments were obtained from Charles River Laboratories. NB9464 (4 x 106) cells were injected subcutaneously into syngeneic 4–6-week-old SykMC-WT or SykMC-KO or C57BL/6 mice. For inhibitor experiments, NB9464-bearing mice received 50 mg/kg R788, or 200 µg anti-PDL1 (clone 10F.9G2, Bio-X-cell) or isotype control LTF2 (Bio X cell) or one dose of 10Gy radiation using a SmART radiator.
3
Immunotherapy and Tumor Imaging in Mice
4
Immune Checkpoint Blockade and HSV-1+Mito-C Combination Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The immune checkpoint blockade antibodies anti-CTLA-4 (clone 9H10, BioXcell), and anti-PDL-1 (clone 10 F.9G2, BioXcell) were used alone or in combination with HSV-1+Mito-C. For ICI treatments, mice with palpable tumors volume below 100 mm3 were injected with 200 μg of the antibodies every 3 days. In the combination treatments ICI antibodies were applied at the same day as the start of HSV-1 treatment. Treatments were continued until mice reached end point. Monoclonal antibodies targeting CD4 (clone GK1.5, BioXcell) and CD8 (Clone 2.43, BioXcell) T cells were administered intraperitoneally at a dose of 250 μg starting 2 days before treatment and applied every other day for the first two weeks and once a week thereafter. Depletion of cells after antibody administration was verified by flow cytometry.
5
Subcutaneous Tumor Implantation and Anti-PD-L1 Therapy in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Inbred C57BL/6J (B6) mice were originally obtained from The Jackson Laboratory and subsequently maintained at the Francis Crick Institute’s animal facilities. Eight- to 12-week-old male mice were used for all experiments, randomly assigned to the different treatment groups. All animal experiments were approved by the ethical committee of the Francis Crick Institute and conducted according to local guidelines and UK Home Office regulations under the Animals Scientific Procedures Act 1986 (ASPA) (licence number: PCD77C6D0). For tumour studies, 1 × 106 MCA-38 derivative cell lines were subcutaneously inoculated into the right flank of recipient mice. Where indicated, mice received intraperitoneal (i.p.) injections of 200 μg anti-PD-L1 (clone 10F.9G2; BioXCell) on days 1, 3, 5, and 7 after tumour inoculation.
6
Cardiac Transplantation and Immune Checkpoint Blockade
7
Anti-PD-L1 Immunotherapy in Tumor Models
8
Surface Receptor Profiling and Tethering Analyses
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For surface receptor profiling analyses, anti-human CD45 (clone 2D1), anti-human CD11a (clone Hi111), anti-human CD18 (clone CBR1FA1/2), anti-human CD2 (clones RPA2.1 and TS1/8), anti-human CD4 (clone SK3), anti-human CD8 (clones Hit8a and SK1), anti-human CD3 (clones Hit3a and UCHT1), anti-human IL-12Rβ1 (clone 69310), anti-human IL-12Rβ2 (clone s16020B), anti-human IL-7R (clone A019D5), anti-human IL-21R (clone 17A12), anti-human IL-2/IL-15Rβ (clone Tu27), anti-human common γ chain (clone TuGh4), and anti-human PD-1 (clones NaT105 and 2H7) were purchased from BioLegend. For surface-tethering analyses, anti-human (clone C11.5) and anti-mouse IL-12 (clone 15.6) were purchased from BioLegend, and anti-human IL-15 (clone 34559) was purchased from R&D Systems. Anti–phospho-STAT4 (p-STAT4) (pY693, clone 38) and anti–p-STAT5 (pY694, clone 47) were purchased from BD Biosciences. For in vivo studies, anti–IFN-γ (clone XMG1.2), anti–PD-L1 (clone 10F.9G2), and anti-Ly6C (clone Monts 1) were purchased from Bio X Cell. For PMEL-adoptive transfer studies and tumor immune microenvironment studies, antibodies are described in tables S1 and S2.
9
Combination Immunotherapy for Bladder Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For the PD-L1 blockade experiment, 200 μg anti-PD-L1 (clone 10F.9G2, Bio-XCell, West Lebanon, NH, USA) was administered by intraperitoneal injection to orthotopic tumor-bearing rats every 4 days for a total of seven times. For the combination of BCG with anti-PD-L1 experiment, antibody treatments were started from the day of intravesical BCG instillation.
10
Vaccine and Adjuvant Administration Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Vaccines were prepared in sterile, endotoxin-free (<0.05 EU/mL)
PBS (Gibco). For mice, vaccines were administered either subcutaneously in a
volume of 50 μL in each hind footpad or intravenously via the tail vein
in a volume of 200 μL. Adjuvants were either prepared in-house as
previously described33 (link) and
summarized in theSupplementary Materials and Methods or were acquired from commercial
sources: polyIC (InvivoGen, San Diego, CA), anti-CD40 agonist (clone FGK4.5,
BioXCell cat #BE0016–2, West Lebanon, NH), and CpG 1826 (InvivoGen).
polyICLC (Hiltonol) was a kind gift of A. M. Salazar (Oncovir). Animals treated
with checkpoint inhibitor (CPI), anti-PD-L1 (clone 10F.9G2, BioXCell cat
#BE0101), received 200 μg administered by the IP route in 100 μL
PBS. For NHP, SNP-7/8a was formulated in 1 mL PBS for each of 4 SC sites (left
and right deltoid; left and right thigh). Immunizations and blood sampling
occurred with the NHP under anesthesia (10 mg per kg weight ketamine HCl).
PBS (Gibco). For mice, vaccines were administered either subcutaneously in a
volume of 50 μL in each hind footpad or intravenously via the tail vein
in a volume of 200 μL. Adjuvants were either prepared in-house as
previously described33 (link) and
summarized in the
sources: polyIC (InvivoGen, San Diego, CA), anti-CD40 agonist (clone FGK4.5,
BioXCell cat #BE0016–2, West Lebanon, NH), and CpG 1826 (InvivoGen).
polyICLC (Hiltonol) was a kind gift of A. M. Salazar (Oncovir). Animals treated
with checkpoint inhibitor (CPI), anti-PD-L1 (clone 10F.9G2, BioXCell cat
#BE0101), received 200 μg administered by the IP route in 100 μL
PBS. For NHP, SNP-7/8a was formulated in 1 mL PBS for each of 4 SC sites (left
and right deltoid; left and right thigh). Immunizations and blood sampling
occurred with the NHP under anesthesia (10 mg per kg weight ketamine HCl).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!